Evidence map›Paper›PMID 35941510›Full record

SynthesisReproductive sciences (Thousand Oaks, Calif.)2023

Efficacy and Safety of Coenzyme Q10 Supplementation in the Treatment of Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis.

Tianqing Zhang, Qi He, Hao Xiu, ZiZhu Zhang, Yao Liu, Zhenrong Chen, Hengjing Hu

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Reproductive sciences (Thousand Oaks, Calif.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Exploring the protective effects of coenzyme Q10 on female fertility.Frontiers in cell and developmental biology · 2025
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Coenzyme Q10 and Endocrine Disorders: An Overview.Antioxidants (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tianqing Zhang *Department of Cardiology, The First Affiliated Hospital of University of South China, Hunan Province, Hengyang, China.
Qi He *Department of Cardiology, The First Affiliated Hospital of University of South China, Hunan Province, Hengyang, China.
Hao XiuDepartment of Cardiology, The First Affiliated Hospital of University of South China, Hunan Province, Hengyang, China.
ZiZhu ZhangDepartment of Cardiology, The First Affiliated Hospital of University of South China, Hunan Province, Hengyang, China.
Yao LiuDepartment of Cardiology, The First Affiliated Hospital of University of South China, Hunan Province, Hengyang, China.
Zhenrong ChenDepartment of Cardiology, The First Affiliated Hospital of University of South China, Hunan Province, Hengyang, China.
Hengjing HuDepartment of Cardiology, The First Affiliated Hospital of University of South China, Hunan Province, Hengyang, China. bestmanhhj123@163.com.ORCID http://orcid.org/0000-0002-1187-3611
First Affiliated Hospital of University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study is to evaluate the efficacy and safety of coenzyme Q10 supplementation in the treatment of polycystic ovary syndrome (PCOS). We first searched PubMed, Wanfang Data, CNKI, Embase, ClinicalTrial.gov, and other databases. The retrieval time from the establishment of the database to January 2021. We collected relevant randomized controlled trials (RCTs) about coenzyme Q10 in the treatment of PCOS. Risk of bias assessment and meta-analysis of RCTs were performed using RevMan 5.0 software. This systematic review and meta-analysis include a total of 9 RCTs involving 1021 patients. The results show that the addition of coenzyme Q10 may improve insulin resistance (HOMA-IR (WMD - 0.67 [- 0.87, - 0.48], P < 0.00001); fasting insulin (WMD - 1.75 [- 2.65, - 0.84], P = 0.0002); fasting plasma glucose (WMD - 5.20 [- 8.86, - 1.54], P = 0.005)), improve sex hormone levels (FSH (SMD - 0.45 [0.11, 0.78], P = 0.009); testosterone (SMD - 0.28 [- 0.49, - 0.06], P = 0.01)), and improve blood lipids (triglycerides (SMD - 0.49 [- 0.89, - 0.09], P = 0.02); total cholesterol (SMD - 0.35 [- 0.56, - 0.14], P = 0.001); LDL-C (SMD - 0.22 [- 0.43, - 0.01], P = 0.04); HDL-C (SMD 0.22 [0.01, 0.43], P = 0.04)). Only one RCT reported adverse events, and they found that patients had no adverse effects or symptoms following supplementation. Based on the current evidence, it could be considered that the addition of CoQ10 is a safe therapy to improve PCOS by improving insulin resistance (reduce HOMA-IR, FINS, FPG), increasing sex hormone levels (increase FSH, reduce testosterone), and improving blood lipids (reduce TG, TC, LDL-C, and increased HDL-C).

Indexed as

Insulin ResistancePolycystic Ovary SyndromeCholesterol, LDLDietary SupplementsFemaleFollicle Stimulating HormoneGonadal Steroid HormonesHumansLipidsTestosteroneUbiquinoneCholesterol, LDLcoenzyme Q10Follicle Stimulating HormoneGonadal Steroid HormonesLipidsTestosteroneUbiquinoneCoenzyme Q10Meta-analysisPolycystic ovary syndromeSystematic review

Identifiers

PMID35941510
OpenAlexW4292283754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.